Good afternoon, ladies and gentlemen, and welcome to the Champions Oncology’s Second Quarter Fiscal Year 2022 Earnings Call. At this time, all participants are in a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Dr. Ronnie Morris. Sir, the floor is yours.

Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. Before I begin, I will remind you that we will be making forward-looking statements during today's call and that actual results could differ materially from what is described in those statements. Additional information and factors that could cause results to differ is available in our Forms 10-Q and Form 10-K. A reconciliation of the non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release. Overall, we had another good quarter with solid growth in our Services business as well as progress in our software and drug discovery efforts. Our Oncology Research Services business had record revenues, while our bookings remain robust. We both continue to expand our service offerings and expand our customer base paving the way for continued growth. We continue to be encouraged by Lumin, our new software platform that was rolled out a little more than a year ago. We have been licensing this platform to our customers using a SaaS model, and our Lumin customer base now stands in excess of 150 users. While our ultimate goal is to build a significant user base, our efforts over this past year have primarily focused on further developing the platform such as adding datasets, improving the user interface, and integrating customers feedback into our software. Our goal is to create an indispensible tool which will lead to a broader user base and result in a significant recurring revenue stream in the coming years. In conjunction with our Lumin software platform, we've launched Lumin Acuity and Lumin Workspaces. In Lumin Acuity, we provide consulting and support services to help…

Thanks Ronnie. Our full results on Form 10-Q will be filed with the SEC later today. Our second quarter financial results were strong with record revenue of $11.8 million compared to $10.1 million in the year ago period, an increase of $1.7 million or 17%. We generated operating income of $263,000, and excluding stock based compensation and depreciation we recognized operating income of approximately $750,000 compared to $400,000 in the year ago period. Focusing as we do on results excluding noncash expenses, such as stock comp and depreciation, our second quarter gross margin was 53% compared to 45% for the same period last year. Total cost of sales was $5.5 million compared to $5.6 million in our second quarter last year. As we discussed on several prior calls, our quarterly gross margins were pressured because we outsourced some lab work to accelerate revenue growth. By minimizing our reliance on outsourcing, we have reduced our total cost of sales even with increases in compensation, lab supplies and rent, resulting from the increase in study volume and our recent lab expansion. Over the last few years, we've continued to invest in our business to adequately support our anticipated growth. As our revenue increases, and with much of the investment costs already incurred, we are realizing the leverage and anticipated improvement in gross margin. It's also worth noting the gross margin improvement has mainly been from our core business. As higher margin products contribute more meaningfully to total revenue, there is room for additional upward trend in margin over the longer term. R&D expense was approximately $2.3 million compared to $1.6 million in the year ago period, an increase of $700,000 or 39%, [indiscernible] $2.3 million and overall increase is in line with guidance provided. As we indicated, we will be ramping up…

[Operator Instructions] Your first question is coming from Matt Hewitt with the Craig-Hallum. Your line is live.

Good afternoon, gentlemen and thank you for taking the questions. Maybe to kick things off just a couple items on Lumin, obviously a nice jump in the number of users here this past quarter up to 150. I'm just curious what the feedback is from those customers that have been on board for maybe the past year, and what's driving some of the new adoption?

Thanks. Thanks, Matt. So I think the feedback continues to be strong. People are getting used to using Lumin. I think a lot of the new users are -- haven't really used it enough to really understand what their adoption is. I think what we've learned is that we have to support people. We have to help them become higher users, more of a user. This is a new technology. This is a new software and what we've learned through the first year is that we need to support them more. We need to help them understand how to become a better user on the platform. So, overall as we support people, as people use Lumin more, I think that what we've gotten back is a very positive response. I would still put us in the category of the early learning. We continue to grow the user base. We continue to grow the functionality. We think the platform is getting stronger, but we're still kind of in that early stages where we're getting a lot of feedback, where we are working with the users, and we're trying to get them to be using it more and more.

Got it. And then it sounds like you've added a new sales team, specifically geared towards that Lumin platform. How many members are on that team? Maybe what was their prior experience before joining champions? And is some of their role going to be on the support side or are they purely out finding new customers?

Yes, I would say it's a mixture. We have four members of the Lumin team right now that do a combination of support and sales. I would say one of the changes we've made as of late is really getting our whole sales force more in tune with Lumin, so that they can also be out there more talking to our customers as well and becoming more proficient within Lumin so that they can try to bring some of our customers along, and bring it to our internal sales group. So, at this point, I think a lot of it is both sales, but also support in terms of getting users up to speed. In terms of support for the software itself, from a technical perspective, we have a whole team that supports that outside of this team.

Got it? Okay, maybe shifting gears a little bit, I've got two questions, and then I'll hop back in the queue. First up, maybe you could update us on the flow cytometry pipeline, how that's progressing? And then I guess the last question would be regarding the European lab that is officially opened as of or opened during the quarter, if you could give us an update on how those discussions are going and whether or not you've started to generate revenues out of that facility? Thank you.

Yes, so in terms of the Europe, both questions kind of go together, we opened up the European site so we can be, so we can better be in a position to do more of the larger flow cytometry and also, I would say the biomarker in general studies, clinical studies. The lab just opened. We opened it a couple months ago, but it just opened to be able to start doing some work and some validation. So, we really haven't seen any shift in that respect, because we're literally just being able to validate some of our assays there. So, I expect over the next quarter or two, we should see a real movement in whether we have the ability to win some of these larger studies. In terms of the biomarker business, in general, it's something that we're still excited about. I think we've made great strides. Operationally, I think we've also done well bringing in some of the business. You know, probably honestly, not as robust as I expected, and I think I've mentioned that before on this call not what we expected. I still believe we will get there, but it certainly hasn't taken the trajectory that we thought it would. I still would say that, as I look to champions, two years from now, I still see it as a large percent, a significant contributor to our growth, but it really hasn't played out that way as of yet. A lot of the other parts of the business have grown at a faster pace. I do like the signs that we're seeing in terms of just the work that we're doing, the quality of the conversations we're having with our customers, the teams that we've built, and I think it's just a matter of time. It's certainly taking a little bit longer than I expected though.

Understood. Great, thank you for taking the questions.

You're welcome Matt.

Your next question is coming from Scott Henry. Your line is live.

Thank you and good afternoon. Just a couple of questions. First another strong sequential gain from first quarter to second quarter of fiscal '22. Would you care to make any comments on the second half of the year? I believe we're thinking about sequential gains in the next two quarters as well, perhaps even larger gains, so just any thoughts you have on that would be great?

Sure. I'll take that quickly. So, I do anticipate that we'll have sequential gain in the second half of the year over the first half of the year, but there's no need to change any of the guidance that's currently been provided. We will be towards the higher end of the guidance, but there's no need to change it at this point.

Okay. Perfect, thank you. And then the gross margin of 52% in 2Q, do you expect I mean, that was a pretty good number, it was a pretty good number in the first quarter as well, can we expect those levels to stay that high throughout the second half of the year?

I do anticipate that those levels are, those are the levels that where we should be near. The slight book fluctuations, but I certainly see that and yes overall steadying of the margins at the 50% level, and with an upward trend over the longer term.

Okay, great. And then one more model question, I think R&D was $2.3 million in 2Q.

Correct.

I believe you said it's going to step up in the second half of the year. What size magnitude? Are we talking about a couple $100,000 per quarter here or larger than that?

Potentially slightly larger than that. The exact timing of when we're going to hit the -- have the ramp up is difficult to predict. But I would anticipate, we are planning on bumping that number up by several $100,000 over the next, you know, each quarter.

Okay, but it sounds like that may be more pronounced in the fourth quarter than the third quarter, did I hear that correctly?

It's really simply a matter of timing being with some of the planned spend, so it will be exactly where it was, it could be Q3 or Q4. It's hard to tell right now.

Okay, great. And then the final question, you mentioned the six targets in the proprietary pipeline, how should we think of the timeline to either partner those programs or reach an inflection point? I mean, are we thinking a year out or are we thinking two years out? Just trying to get a sense of when we may see some catalysts on that front?

Yes, I think it's in between those two numbers you put out there, Scott, I think it's between a year and two years that that will be at the point, will either be at an IND enabling stage or it will be at a point where we will out license or partner. So I think that that's a reasonable kind of goalpost.

Okay, great. Thank you for taking the questions.

You're welcome, sure.

We have no further questions from the lines at this time. I would like to turn the floor back to Dr. Ronnie Morris, for closing remarks.

Thank you. And thank you, everybody, for joining us for our quarterly earnings call. We're certainly excited about the direction we're taking with the expansive services business as well as our two new efforts, which include the SaaS platform, our software platform, as well as our drug development. This is an incredibly exciting time for Champions Oncology. We feel we're on the right path, and we're at an inflection point. So we look forward to continuing our updates over the next couple quarters with everybody on this call. Thank you and have a good evening.

Thank you. Ladies and gentlemen, this concludes today's event. You may disconnect at this time and have a wonderful day. Thank you for your participation.